Company News, Media 14 Jun 2024 Petra Capital Research Report | June 2024 Petra Capital has released research report, forecasting Orthocell’s potential to reach A$1.28 per share. Orthocell
Company News 11 Jun 2024 Orthocell applies for TGA market approval for SmrtGraft™ Orthocell has applied to the Therapeutic Good Administration (TGA) for Australian market approval for its SmrtGraft™ tendon repair device, in… Orthocell
Company News 30 Apr 2024 Remplir™ nerve repair study published in peer-reviewed clinical journal Orthocell has announced that results from the Remplir™ nerve regeneration clinical trial have been published in a high profile clinical… Orthocell
Company News 15 Apr 2024 Orthocell receives $3.05m R&D tax incentive refund Orthocell has announced that it has received a Research and Development (R&D) Tax Incentive refund of A$3,051,483 for the financial… Orthocell
Company News 08 Apr 2024 Quarterly Report – Period To 31 March 2024 Orthocell has today published its Quarterly Report for the period ended 31 March 2024. Orthocell
Company News 25 Mar 2024 Orthocell Successfully Completes Surgeries for Remplir™ US Market Authorisation Orthocell has announced that it has successfully completed the first stage of the Remplir™ US 510(k) market authorisation nerve repair… Orthocell
Company News 22 Feb 2024 Orthocell Completes $3.5M Strategic Placement Orthocell has today announced that it has completed a Company-led Strategic Placement to raise $3.5 million. Orthocell
Company News 13 Feb 2024 Orthocell submits Singapore Regulatory Application for Remplir™ Orthocell has today announced that the Company has submitted a regulatory application to the Health Services Authority of Singapore for… Orthocell
Company News 15 Jan 2024 The Hon Kim Beazley AC Joins Orthocell Board Orthocell has appointed Australia’s former US ambassador and Governor of Western Australia, The Hon Kim Beazley AC, as an Independent… Orthocell
Company News 14 Nov 2023 Positive clinical results for OrthoATI™ Orthocell has today released positive results from our clinical study comparing OrthoATI™ to surgery for the treatment of severe chronic… Orthocell
